Progress of research on mTOR inhibitor in endocrine and HER-2 targeted therapy resistance in breast cancer

VernacularTitle:mTOR 抑制剂在乳腺癌内分泌及 HER-2靶向治疗耐药中的研究进展
Author: Haiming DUAN ; Yanni ZHENG ; Minquan WANG
Publication Type:Journal Article
Keywords: Breast neoplasms; Sirolimus; mTOR inhibitor
From: Journal of International Oncology 2015;(5):377-380
CountryChina
Language:Chinese
Abstract: Mammalian target of rapamycin(mTOR)locates at the downstream of phosphatidylinositol 3 kinase(PI3K)-protein kinase B(Akt)cell signal transduction pathway. Studies find that the abnormal activa-tion of this pathway is correlated with the endocrine and drug resistance of anti human epidermal growth factor receptor-2(HER-2)target therapy in breast cancer. The combination with mTOR inhibitors based on the past traditional drugs can block the pathway and reflect a favourable application prospect in preventing the develop-ment of resistance and restoring the initial sensitivity on tumor cells. mTOR inhibitors are expected to be the new hope for the treatment of breast cancer.